Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Benjamin Wisner

Urology Fort Collins, CO Medical Doctor

NPI 1396891982 CMS profile 431761

2315 E Harmony Rd, Ste 140, Fort Collins, CO 80528

Open in the dashboard

General payments

$1,600

29 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Wisner of Fort Collins, CO is reported in the CMS Open Payments database as having received $1,600 across 29 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $660 13
2024 General $765 12
2023 General $99 2
2022 General $76 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Wisner
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Benjamin Wisner were reported at $660. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Benjamin Wisner Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $0 $358 $111–$1,000 $132
2022 $76 $476 $143–$1,263 $149
2023 $99 $560 $168–$1,461 $160
2024 $765 $563 $170–$1,464 $164
2025 $660 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Intuitive Surgical, Inc. $769 9 payments
  2. Boston Scientific Corporation $182 8 payments
  3. Caldera Medical, Inc $140 1 payment
  4. Axonics Modulation Technologies, Inc. $127 2 payments
  5. Astellas Pharma US Inc $105 1 payment
  6. Swan Valley Medical Incorporated $82 1 payment
  7. Allergan Inc. $50 1 payment
  8. AbbVie, Inc. $48 2 payments
  9. Immunitybio, Inc. $33 1 payment
  10. PROCEPT BioRobotics Corporation $29 1 payment
  11. Other $35 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,480 27 payments
  2. Education $111 1 payment
  3. Gift $9 1 payment
Products named General payments · program years 2022–2025
  1. Da Vinci Surgical System $769 9 payments
  2. Axonics $143 3 payments
  3. XTANDI $105 1 payment
  4. Advantage System $83 4 payments
  5. Upsylon $83 3 payments
  6. BOTOX Urology $50 1 payment
  7. BOTOX Botox Therapeutic $48 2 payments
  8. ANKTIVA $33 1 payment
  9. AQUABEAM ROBOTIC SYSTEM $29 1 payment
  10. NANOKNIFE $20 1 payment
  11. Other $34 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

767

Median for Urology: 1,053

Drug cost

$194,634

Median for Urology: $101,464

Branded share of claims

53.7%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 154 $120,565
Gemtesa Vibegron Brand 72 $53,837
Estradiol Generic 171 $12,263
Solifenacin Succinate Generic 62 $3,114
Oxybutynin Chloride Er Oxybutynin Chloride Brand 134 $3,002
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 34 $1,075
Tamsulosin Hcl Generic 33 $454
Cephalexin Generic 78 $263
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 18 $49
Oxycodone Hcl Generic 11 $12

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$161,272

Of which drugs: $37,163

Medicare patients

366

Average age 75

Services billed

8,699

314 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 57%
Depression 29%
Osteoporosis 24%
Ischemic heart disease 22%
Chronic kidney disease 18%
Diabetes 17%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 30 6,601 $32,884

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

29 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record